Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement

MLA

Apostolia M. Tsimberidou, et al. “Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement.” Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, Oct. 2018, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s40425-018-0426-7.

APA

Apostolia M. Tsimberidou, Laura A. Levit, Richard L. Schilsky, Steven D. Averbuch, Daniel Chen, John M. Kirkwood, Lisa M. McShane, Elad Sharon, Kathryn F. Mileham, & Michael A. Postow. (2018). Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. Journal for ImmunoTherapy of Cancer, 6(1), 1–10. https://doi.org/10.1186/s40425-018-0426-7

Chicago

Apostolia M. Tsimberidou, Laura A. Levit, Richard L. Schilsky, Steven D. Averbuch, Daniel Chen, John M. Kirkwood, Lisa M. McShane, Elad Sharon, Kathryn F. Mileham, and Michael A. Postow. 2018. “Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement.” Journal for ImmunoTherapy of Cancer 6 (1): 1–10. doi:10.1186/s40425-018-0426-7.